Skip to main content
. Author manuscript; available in PMC: 2022 Jul 17.
Published in final edited form as: Nat Metab. 2022 Jan 17;4(1):44–59. doi: 10.1038/s42255-021-00515-3

Fig. 1. Inhibition of HDAC6 Reverses Diet-Induced Obesity.

Fig. 1.

a, b, Effect of daily intraperitoneal (i.p.) Tubastatin (TubA, 25 mg/kg, n= 6) or vehicle (Veh, n= 6) administration on wild-type DIO mice: a, Body weight (P=2.6E-9), b, cumulative food intake of the animals (P=1.7E-5). c, Body weight (P=1E-4) and d, food intake (week 1 P=0.0012, week 2 P=7E-6, week 3 P=0.00097) of TubA-treated WT (n=17) and HDAC6 KO (n= 14) DIO mice. e, Lean and fat mass of DIO mice determined by nuclear magnetic resonance (NMR) before and 32 days after TubA or Veh treatment (n= 6 per group, Fat mass at 32 days P= 1.4E-7). f, Plasma leptin concentration of DIO mice before and 32 days after tubastatin treatment (n= 6, P=0.0016). g-j, Food intake and growth curves of wild-type mice on regular diet (chow) or HFD treated by daily i.p. vehicle or tubastatin (25 mg/kg) (n=9 mice per group) For i, week1 P=0.0014, week2 P=0.00043, week 3 P=0.042, week4 P=0.037); j, P=1E-10). *P<0.05, **P<0.01, ***P<0.001 as analyzed by one-way or two-way analysis of variance (ANOVA) or mixed-effect analysis with Tukey’s post-hoc test for multiple comparison, or two-tailed Student’s t-test. Data are represented as mean ± s.e.m.